VBIO

Business Context and Reporting Period

Company: Tivic Health Systems, Inc. (Ticker: TIVC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Tivic Health is a health tech company developing non-invasive bioelectronic medicine. Its primary commercial product is ClearUP Sinus Pain Relief, an FDA-approved handheld device for sinus pain and congestion. The company is also advancing a research-stage platform for non-invasive vagus nerve stimulation (ncVNS).

Key Financial Metrics

Note: Q2 2023 per share data reflects a 1-for-100 reverse stock split effective August 2023; historical figures have been restated.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 13% in Q2 2024 and 12% for the six months ended June 30, 2024, compared to the prior year. The six-month decline was primarily driven by a 27% decrease in unit sales, partially offset by a 20% increase in average sales price.
• Expense Reduction: Total operating expenses decreased significantly, dropping 43% in Q2 and 35% for the six-month period. This was driven by reduced headcount and lower professional fees across R&D, Sales & Marketing, and G&A.
• Improved Loss Profile: Net loss narrowed by 40% in Q2 and 35% for the six-month period compared to 2023, reflecting the substantial reduction in operating expenses.
• Capital Raise: In May 2024, the company completed a registered public offering, selling 4.71 million shares and warrants for net proceeds of approximately $3.3 million.
• Lease Termination: The company terminated its primary office lease in May 2024, incurring a $60,000 loss but expecting to reduce lease expenses by approximately $200,000 over the next 18 months.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. With a cash balance of $3.7 million and a burn rate resulting in negative operating cash flows of $3.0 million for the first half of 2024, the company expects to require additional capital to fund operations and R&D.
• Nasdaq Compliance: The company received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement (stock price below $1.00 for 33 consecutive days). The company has 180 days (until December 26, 2024) to regain compliance or risk delisting.
• Operational Updates:
  • Launched ClearUP 2.0 with improved battery life and power management.
  • Terminated the fulfillment agreement with ALOM Technologies to reduce costs and transition to in-house assembly and alternate logistics providers.
  • Received positive pilot data from a study with The Feinstein Institutes regarding ncVNS efficacy, though a subsequent study on postoperative pain showed no statistically significant difference between active and sham devices.
• Risks: Key risks include the inability to secure additional financing, potential delisting from Nasdaq, supply chain disruptions, and the failure of new product candidates to achieve regulatory approval or market acceptance.

Investor Verification Checklist

• Liquidity Runway: Verify the company's specific timeline for raising additional capital given the "substantial doubt" disclosure and current cash burn rate.
• Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 threshold for 10 consecutive days before the December 26, 2024 deadline to avoid delisting proceedings.
• Revenue Trends: Assess whether the decline in unit sales is a temporary fluctuation or a structural issue affecting the core ClearUP product.
• Capital Structure: Review the dilution impact of the 12 million+ warrants outstanding, many of which have low exercise prices ($0.85 - $0.935).
• Cost Structure: Confirm that the cost savings from lease termination and the ALOM agreement termination are fully realized in future quarters.